

Index

A

ACBD3, 246–247
N-Acetylglucosaminyltransferase I, 175
ADAM10, 242
ADAM17, 242
AKAPs, 213
 α -Dystroglycan, glycosylation, 42
 α PS1 integrin, Golgi bypass, 273–274
 α -SNAP, 177
ALPS motif, 112
Amyloid precursor protein (APP), *trans*-Golgi retrograde transport, 190
Ang 2, 159
Anterograde vesicular transport between stable compartments model. *See* Trafficking models
AP-1, 90, 163, 166, 184, 207, 291
AP-2, 90, 164–165, 184
AP-3, 90, 164
AP-4, 90, 163
Apoptosis, Golgi fragmentation and loss of positioning, 228–229
APP. *See* Amyloid precursor protein
Architecture, Golgi
 cis-face
 endoplasmic reticulum exit site, 5–6
 vesicular tubular cluster, 6
 comparative structure, 256–257
 Golgi stack, 7–9
 noncompact zone, 9–10
 overview, 2–5
 trans-Golgi network
 higher order organization by tethers, 189–190
 overview, 11
 physical structure, 188–189
 variability by cell type, 13–14
Arf1
 early secretory pathway function, 91, 94–101
 Golgi *cis*-face entry/exit role, 81–82
 localization, 149
 protein kinase D recruitment to *trans*-Golgi network, 197–198, 201
 proteomics, 176, 178
 signaling function, 207
ArfGAP1, 100
ArfGAP2/3, 100

ARFGEF2, 247
Arl1, 157, 186
Arl3, 149
Arp1, 221–222
ATPSK2, 43
AUGUSATIFOLIA, 294–295
Axon, specification, 230–231

B

BACE, 183, 190
BARS. *See* Brefeldin-A ADP-ribosylated substrate
BBsome, 90
Bet1, 79–80, 130
 β -Spectrin, 223
BFA. *See* Brefeldin A
B4GALT7, 43
B3GALT1L, 44
BICD-2, 224
Biogenesis, Golgi
 Golgi structure in different organisms, 256–257
 mammalian mechanisms
 disassembly
 biological significance, 257–259
 cisternae vesiculation and unstacking, 259–260
 daughter cell partitioning, 260
 Golgi ribbon unlinking, 259
 reassembly
 cisternal stacking, 262
 membrane fusion pathways, 261–262
Brefeldin A (BFA)
 Golgi bypass induction, 274
 mechanism of action and effects by cell type, 271–272
 resistance in Golgi bypass, 270
Brefeldin-A ADP-ribosylated substrate (BARS), 99, 258–259, 289, 292–293
Bug1, 76
Bypass, Golgi
 atypical endoplasmic reticulum exit via COPII-independent vesicles, 269
 brefeldin A induction, 274
 cargo bypassing Golgi
 α PS1 integrin, 273–274
 CD45, 273
 connexins, 273

Index

- Bypass, Golgi (*Continued*)
cystic fibrosis transmembrane conductance regulator, 274
detection
brefeldin A resistance, 270
EndoH sensitivity, 270
SNARE independence, 270–271
GRASP protein function, 276–277
overview, 267–269
rationale
ensuring correct Golgi function, 275–276
protection of classical cargo proteins, 275
protein activity regulation, 275
speed, 275
- C**
- Cage proteins, Golgi coats, 162–163
Calcium flux, protein kinase D activation at *trans*-Golgi network, 199
Calnexin, 178–179
cAMP. *See* Cyclic AMP
CASP, 113
CATCHR complexes, 158–161, 167
CD45, Golgi bypass, 273, 275
Cdc42, 229
Cdk1, 260
Ceramide transfer protein (CERT), 200–201, 207, 211
CERT. *See* Ceramide transfer protein
CFTR. *See* Cystic fibrosis transmembrane conductance regulator
CHST6, 44
CHST14, 44
cis-face
COPI-dependent export, 81–82
endoplasmic reticulum exit site, 5–6
endoplasmic reticulum-Golgi intermediate compartment membrane fusion, 74, 78–81
golgins
GM130, 110–112
GMAP-210, 112
Golgin-160
prospects for transport studies, 82–83
vesicle tethering machinery
extended coiled-coil domain tethers, 75–77
overview, 75
TRAPP I, 75, 77–78
vesicular tubular cluster, 6
Cisternae
formation, 261–262
stacking, 262
vesiculation and unstacking, 259–260
Cisternal progenitor model. *See* Trafficking models
Cisternal progression/maturation model. *See* Trafficking models
Cisternal progression/maturation with heterotypic tubular transport model. *See* Trafficking models
CLASP, 190
Clathrin
cage proteins, 162–163
inner coat layer, 163–166
overview, 7, 90
structure, 162–163
trans-Golgi retrograde transport, 185
COG complex. *See* Conserved oligomeric Golgi complex
Connexins, Golgi bypass, 273
Conserved oligomeric Golgi (COG) complex
CATCHR complexes, 158–161
glycosylation disorders, 46–48
lobes, 46
overview, 28
SNARE interactions, 131–132
COPI
budding within Golgi stack
fission proteins, 99–100
overview, 89–91
prospects for study, 100–101
uncoating, 100
vesicle formation
Arf1 cooperation, 99
budding and scission, 98–99
cargo inclusion in vesicles, 97–98
cargo sorting, 96–97
coat recruitment, 94–96
lipids, 93–94
cage proteins, 162–163
cis-face export dependence, 81–82
early secretory pathway role, 91
endocytic pathway role, 92
exit routes from Golgi, 195–196
Golgi stack coats, 10
inner coat layer, 163–166
mitosis and Golgi positioning function, 91
proteomics of transport vesicles, 175–178
SNARE recruitment, 129
structure, 92–93
tether protein interactions, 167
vesicular tubular clusters, 6
COPII
cage proteins, 162–163
endoplasmic reticulum exit site, 5–6
inner coat layer, 163–166
SNARE recruitment, 129
TRAPP I association, 77
COSMC, 45
Coy1, 76
CtBP, 258–259
CTBP1, 293–294
CTBP2, 293–294

Cyclic AMP (cAMP), Golgi signaling, 213–214
Cystic fibrosis transmembrane conductance regulator (CFTR), Golgi bypass, 274–276

D

DAG. *See* Diacylglycerol
Dendrite, arborization, 230–231
Dermatan sulfate, disorders, 44
Developmental biology
 Golgi fragmentation, reconstitution, and intracellular signaling, 244–247
 polarized Golgi distribution and transport in neuronal development, 247–249
 receptor activation modulation
 protein cleavage in Golgi, 238–241
 protein glycosylation in Golgi, 241–244
dGRASP, 276–277
Diacylglycerol (DAG)
 Golgi signaling, 210
 protein kinase D recruitment to *trans*-Golgi network, 197–198
Dpm1, 209
Dsl1 complex, 100, 131
DTDST, 43
Dyn2, 212
Dynein, Golgi positioning, 220–221, 228

E

EB1, 222
EDEM1, 269, 276
EGFR. *See* Epidermal growth factor receptor
EHD3, 184
Ehlers–Danlos syndrome, 43
Elks-1, 116
Endoglycosidase H, 26, 270
Endoplasmic reticulum (ER)
 atypical endoplasmic reticulum exit via COPII-independent vesicles, 269
 glycosylation localization, 36–37
 Golgi stack interactions, 9
Endoplasmic reticulum exit site (ERES), 5–6
Endoplasmic reticulum-associated degradation (ERAD), 269
Endoplasmic reticulum-Golgi intermediate compartment (ERGIC)
 cis-Golgi compartment membrane fusion, 74, 78–81
 exit routes from Golgi, 195–196
Epidermal growth factor receptor (EGFR), activation in development, 238–239, 241
Epidermal growth factor repeat, glycosylation, 27, 44
ER. *see* Endoplasmic reticulum
ERAD. *See* Endoplasmic reticulum-associated degradation

ERC1, 115
ERC2, 115
ERES. *See* Endoplasmic reticulum exit site
ERGIC. *See* Endoplasmic reticulum-Golgi intermediate compartment
ERGIC-53, 100
ERO1, 180
ERp44, 179–180
ESCRT, 90, 287
Evolution, Golgi
 comparative structure, 256–257
 diversity among eukaryotes, 287–288
 eukaryotic lineages, 284–286
 glycosylation
 cell surface glycosylation, 302–304
 Golgi mediation of red queen effects, 307
 overview, 301–302
 pathogens
 attachment to glycans by pathogens and symbionts, 304–305
 evasion with glycan molecular decoys, 306–307
 host glycan change response for survival, 305–306
 immune recognition, 306
 intrinsic functions of host glycans, 305
 mimicry, 306
 prospects for study, 309–310, 312
 variation of glycans
 N-glycans, 307–308
 O-glycans, 308
 glycophospholipid anchors, 309
 glycosaminoglycans, 309
 glycosphingolipids, 308
 outer extensions of glycoprotein and glycolipid glycans, 308–309
 sialic acids, 309, 311
 Golgi proteins, 289–290
 homology searching, 290–291
 membrane trafficking system, 286–287
 pre-last common eukaryotic ancestor, 295–296

Exomer, 90
EXT1, 43
EXT2, 43

F

Familial tumor calcinosis (FTC), 44–45
FAPP2, 200, 207–208
FCMD. *See* Fukayama-type congenital muscular dystrophy
FECA. *See* First common eukaryotic ancestor
Fenestrae, 8
FGF. *See* Fibroblast growth factor
FGF-23. *See* Fibroblast growth factor-23

Index

- Fibroblast growth factor (FGF), Golgi signaling in development, 243–244
- Fibroblast growth factor-23 (FGF-23), mutations, 45
- First common eukaryotic ancestor (FECA), 296
- Fringe, 243
- Frq1, 210
- FTC. *See* Familial tumor calcinosis
- Fukayama-type congenital muscular dystrophy (FCMD), 42
- Fukutin, 42
- G**
- GAG. *See* Glycosaminoglycan
- GALNT3, 44–45
- GARP complex, 159
- GARP/VFT complex, 130–131
- GAT domain, 166
- GCC88, 186, 188
- GCC185, 157–158, 186, 188, 190
- GCP16, 112
- GCP60, 112
- GGA proteins, 163, 166, 184
- Gigantin, 113
- Glycophosphatidylinositol (GPI) anchor disorders, 45–46
- overview, 21, 27
- variability and evolution, 309
- Glycosaminoglycan (GAG) disorders
- chain elongation disorders, 43–44
- chain initiation disorders, 43
- overview, 42–43
- substrate limitation, 43
- overview, 26
- variability and evolution, 309
- Glycosphingolipids, variability and evolution, 308
- Glycosylation. *See also* Glycosyltransferases disorders
- conserved oligomeric Golgi complex disorders, 46–48
- glycophosphatidylinositol anchor disorders, 45–46
- glycosphingolipid disorders, 45
- N*-glycosylation, 37, 41
- O*-glycosylation, 42–45
- golgin mutations, 49
- lipid homeostasis and trafficking, 50
- overview, 35–37
- prospects for study, 50–51
- SEC protein mutations, 49–50
- table of disorders, 38–41
- transporter mutations, 41–42
- vacuolar ATPase mutations, 48–49
- endoplasmic reticulum, 36–37
- evolution
- cell surface glycosylation, 302–304
- Golgi mediation of red queen effects, 307
- overview, 301–302
- pathogens
- attachment to glycans by pathogens and symbionts, 304–305
- evasion with glycan molecular decoys, 306–307
- host glycan change response for survival, 305–306
- immune recognition, 306
- intrinsic functions of host glycans, 305
- mimicry, 306
- prospects for study, 309–310, 312
- variation of glycans
- N*-glycans, 307–308
- O*-glycans, 308
- glycophospholipid anchors, 309
- glycosaminoglycans, 309
- glycosphingolipids, 308
- outer extensions of glycoprotein and glycolipid glycans, 308–309
- sialic acids, 309, 311
- glycans as tags for research, 28–30
- glycophosphatidylinositol anchor, 21, 27
- N*-glycosylation, 26
- O*-glycosylation, 26–27
- lipids, 27
- overview, 21–22, 36
- receptor activation in development, 241–244
- regulation, 27–28
- sugars added and removed by Golgi, 25
- Glycosyltransferases (GTs)
- general characteristics, 22–24
- glycan types, 21–22
- Golgi retention mechanisms, 146–147
- Golgi targeting, 24–25
- reactions, 24
- GM130, 10, 76, 100, 110–112, 229–230, 259, 261
- GMAP210, 49, 112, 157–158, 224, 226, 230
- GOLGA6A-J, 111
- GOLGA8A-J, 111
- GOLGA6AL1-10, 111
- Golgi biogenesis. *See* Biogenesis, Golgi
- Golgi bypass. *See* Bypass, Golgi
- Golgi evolution. *See* Evolution, Golgi
- Golgi positioning. *See* Positioning, Golgi
- Golgi protein retention. *See* Protein retention, Golgi
- Golgi stack
- architecture, 7–9
- COPI coats and budding. *See* COPI
- interface between Golgi stack, vesicular tubular cluster, and *trans*-Golgi network, 6–7
- rim golgins, 113

- Golgin-67
Golgin-84, 113
Golgin-97, 113, 186
Golgin-160
Golgin-245, 186
Golgins. *See also specific proteins*
 cis-Golgi
 GM130, 110–112
 GMAP-210, 112
 Golgin-160
 Golgi stack rim, 113
 modeling of function, 116–118
 overview, 109–110
 regulation, 116
 structure, 156–158
 trans-Golgi
 GRIP domain golgins, 113–114, 186
 TMF, 114
GOLPH3, 146–147, 179, 208
GOPC, 112–113
Gos28, 276
GPI anchor. *See* Glycophosphatidylinositol anchor
GPP34, 179
GRAB domain, 157
GRASP55, 10, 155, 258–260, 262, 276–277
GRASP65, 10, 65, 110, 155, 229–231, 258, 260, 262,
 276–277, 290
Grh1, 76
GRIP domain golgins, 113–114, 157, 186
GS15, 130, 185
GTs. *See* Glycosyltransferases
- H**
- Heparan sulfate, disorders, 43
Hereditary multiple exostosis (HME), 43
HME. *See* Hereditary multiple exostosis
Hook3, 226
- I**
- Ilimaquinone (IQ), 196–197
IQ. *See* Ilimaquinone
- K**
- KDEL proteins and receptors, 96, 98, 178, 213
KIFC-3, 221
- L**
- LARGE, 42
Last common eukaryotic ancestor (LECA). *See also*
 Evolution, Golgi
 homology searching, 290–291
 membrane trafficking system, 286–287
- LC3, 276
LECA. *See* Last common eukaryotic ancestor
Limb–girdle muscular dystrophy, 42
- M**
- Mabry syndrome, 45
Macular corneal dystrophy, 44
Mannosidase II, 177
MAPK. *See* Mitogen-activated protein kinase
MEB disease. *See* Muscle–eye–brain disease
Microtubule
 Golgi positioning, 220–224, 226
 trans-Golgi network association, 190
Microtubule organizing center (MTOC), 4
Mitogen-activated protein kinase (MAPK). *See also*
 specific kinases
 Golgi disassembly role, 259
 Golgi signaling, 211–213
Mnn9, 147
MTOC. *See* Microtubule organizing center
Munc18, 289
Muscle–eye–brain (MEB) disease, 42
MYO18A208
- N**
- Niemann–Pick disease type C, 50
Nir2, 259–259
Notch
 activation in development, 240–244
 glycosylation, 27, 44
NSF, 124, 148, 188, 261–262, 285
Numb, 244–246
- O**
- Och1, 147
OPH. *See* Organelle paralogy hypothesis
Organelle paralogy hypothesis (OPH), 295
OS-9, 269
OSBP, 200–201, 208
- P**
- p24 proteins, 96, 101
p38, 199, 210
p38, 258
p47, 262
p97, 259, 261–262
p115, 75–77, 116, 132, 156–158, 229, 259,
 261, 290–292
p150, 221–223, 227
Paroxysmal nocturnal hemoglobinuria
 (PNH), 46
Peters plus syndrome, 44

Index

- Phosphatidylinositol-4-phosphate (PI(4)P)
effectors, 207–208
Golgi signaling, 206–210
kinases, 206
- Phospholipase D (PLD), 198
- PI(4)P. *See* Phosphatidylinositol-4-phosphate
- PIGA, 45
- PIGM, 45
- PIGV, 45
- Pik1, 209–210, 260
- PKA. *See* Protein kinase A
- PKC. *See* Protein kinase C
- PKD. *See* Protein kinase D
- PLD. *See* Phospholipase D
- PNH. *See* Paroxysmal nocturnal hemoglobinuria
- Positioning, Golgi
mechanism
cytoskeleton-mediated stabilization, 227
direct binding to microtubules and centrosomes, 224, 226
knockdown studies, 225–226
membrane capture by motors and loading onto microtubules, 220–222
multiple motor regulation and bidirectional movement, 227
overview, 219–220
physiological importance
axon specification and dendrite arborization, 230–231
cell polarization and migration, 230
furrow formation during cellularization, 230
immunological synapse, 230–231
regulation
fragmentation and loss of positioning
apoptosis, 228–229
mitosis, 227–228
membrane remodeling and reorientation
cell differentiation, 229
cell polarization and migration, 229–230
- PP2A, 262
- Presomatic mesoderm (PSM), Golgi in development, 243–244
- Protein kinase A (PKA), Golgi signaling, 213–214
- Protein kinase C (PKC), Golgi signaling, 210–211
- Protein kinase D (PKD)
activation at *trans*-Golgi network, 198–199
Golgi signaling, 210–211
identification as membrane fission inducer, 196–197
modified lipid production at *trans*-Golgi network, 199–201
recruitment to *trans*-Golgi network, 197–198
- Protein retention, Golgi
amino acid sequence-based retention, 145–146
amino-terminal arginine-based motifs, 147
carboxy-terminal lysine-based motifs, 147–148
glycosyltransferases, 146–147
Golgi membrane lipid composition-based retention, 145
overview, 141–143
peripheral membrane protein localization, 149–150
prospects for study, 150
protein aggregation and kin recognition, 144
protein conformation-based retention, 148–149
transmembrane domain-mediated retention, 144–145
- Proteomics
COPI transport vesicles, 175–178
Golgi protein discovery and characterization, 178–180
limitations, 174–175
principles, 173–174
- PSM. *See* Presomatic mesoderm
- Q**
- Q-SNARE proteins. *See* SNAREs
- R**
- Rab1, 76–77, 248, 290
- Rab6, 49, 116, 160, 186
- Rab7, 184
- Rab9, 185, 188
- Rab11, 184
- Raf, 212
- Rapid partitioning in mixed Golgi model. *See* Trafficking models
- Ras, Golgi signaling, 211–213
- Retention. *See* Protein retention, Golgi
- Retromer, 90, 184
- RHOBTB3, 189
- RIG1, 212
- RINT-1, 222
- R-SNARE proteins. *See* SNAREs
- Rud3, 76
- RZZ complex, 222, 228
- S**
- SAC1, 209–210
- Sar1, 248
- SCYL1BP1, 49, 115
- Sec1, 289
- Sec2, 207

- Sec13, 269
Sec15, 207
Sec22, 79, 128, 130
Sec23, 223, 248
SEC23A, 49–50
SEC23B, 49–50
Sec24, 269
SEMD. *See* Spondyloepimetaphyseal dysplasia
Sialic acids, variability and evolution, 309, 311
SIAT9, 45
Sly1, 46, 79, 132–133
SMS1, 210
SMS2, 210
SNAREs
 assembly and disassembly, 123–124
 evolution, 286–287, 289–290
 Golgi SNAREs, 126–128
 independence in Golgi bypass, 270–271
 localization, 128–130
 modeling of function, 133–135
 Q-SNARE proteins, 78–79, 129, 132
 R-SNARE proteins, 78–79, 124
 SM proteins, 132–133
 structure, 124–126
 tethering protein interactions, 130–132
 trans-Golgi retrograde transport role, 185
SNX1, 185
SORL1, 190
SPCA, 249
Spondyloepimetaphyseal dysplasia (SEMD), 43
STX6, 185
STX10, 185, 188
STX16, 185
- T**
- TANGO1, 292–293
T cell, Golgi positioning, 230–231
Tctex-1, 221
TE. *See* Tropoelastin
TGN. *See* *Trans*-Golgi network
Thrombospondin repeats, glycosylation, 27, 44
TIP47, 184–185, 188
Tlg1, 159
TME, 114, 116
Tn syndrome, 45
Trafficking models
 anterograde vesicular transport between stable compartments
 overview, 59–60
 strengths, 59–60
 weaknesses, 60–61
 cisternal progenitor model
 overview, 66–67
 strengths, 67
 weaknesses, 67
 cisternal progression/maturation model
 overview, 61–62
 proteomics, 175–176, 178
 strengths, 61
 weaknesses, 62
 cisternal progression/maturation with heterotypic tubular transport
 overview, 63
 strengths, 63–64
 weaknesses, 64
 ideal criteria, 57–59
 microscopy data fitting, 68–69
 rapid partitioning in mixed Golgi
 overview, 64–65
 strengths, 64–65
 weaknesses, 65–66
trans-Golgi network (TGN)
 architecture, 11
 exits, 11–12
 functional overview, 4
 golgins
 GRIP domain golgins, 113–114, 186
 TME, 114
 interface between Golgi stack, vesicular tubular cluster, and *trans*-Golgi network, 6–7
 microtubules, 190
 protein kinase D role in export.
 See Protein kinase D
 retrograde transport
 cargoes, 181–182
 coats, 184–185
 Rab9 and SNARE function, 185
 RHOBTB3–Rab9 interactions, 188
 sorting, 12–13
 structure
 higher order organization by tethers, 189–190
 physical structure, 188–189
 tethering proteins, 186–188
TRAPP I, 75, 77–78, 80–81, 130
TRAPP II, 130
Tropoelastin (TE), 48
- U**
- Ufe1, 131
Uso1, 76–77, 132, 156–157
- V**
- Vacuolar ATPase, mutations, 48–49
VAMP3, 185
VAMP4, 185
VCIP135, 262

Index

- Vesicular tubular cluster (VTC)
 architecture, 4–6
 interface between Golgi stack, vesicular tubular
 cluster, and *trans*-Golgi network, 6–7
- VHS domain, 166
- Vps4, 188
- Vps45, 132–133
- Vps51, 159, 186
- Vps52, 159–160, 186
- Vps53, 159, 186
- Vps54, 159
- Vps74, 146–147, 179, 208
- Vrg4, 148
- VTC. *See* Vesicular tubular cluster
- W**
- Walker–Warburg syndrome, 42
- Wnt, 243–244
- Y**
- Ykt6, 128, 185
- Ypt1, 77, 79–88
- YSK1, 230
- Z**
- ZW10, 222